regulus therapeutics inc. (nasdaq:rgls) is a biopharmaceutical company leading the discovery and development of innovative medicines targeting micrornas. regulus has leveraged its oligonucleotide drug discovery and development expertise to develop a well-balanced microrna therapeutics pipeline complemented by a maturing micromarkerssm biomarkers platform and a rich intellectual property estate to retain its leadership in the microrna field. regulus is developing rg-101, a galnac-conjugated anti-mir targeting microrna-122 for the treatment of chronic hepatitis c virus infection, and rg-012, an anti-mir targeting microrna-21 for the treatment of alport syndrome, a life-threatening kidney disease driven by genetic mutations with no approved therapy. in addition, rg-125, a galnac-conjugated anti-mir targeting microrna-103/107 for the treatment of nash in patients with type 2 diabetes/pre-diabetes, has entered phase i clinical development through its strategic alliance with astrazeneca. reg
Company profile
Ticker
RGLS
Exchange
Website
CEO
Joseph Hagan
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
IRS number
264738379
RGLS stock data
Latest filings (excl ownership)
10-K
2023 FY
Annual report
21 Mar 24
8-K
Regulus Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Updates
21 Mar 24
8-K
Regulus Therapeutics Announces Oversubscribed $100 Million Private Placement of Equity
14 Mar 24
S-8
Registration of securities for employees
12 Jan 24
EFFECT
Notice of effectiveness
10 Jan 24
CORRESP
Correspondence with SEC
5 Jan 24
UPLOAD
Letter from SEC
2 Jan 24
S-3
Shelf registration
27 Dec 23
10-Q
2023 Q3
Quarterly report
9 Nov 23
8-K
Regulus Therapeutics Reports Third Quarter 2023 Financial Results and Recent Updates
9 Nov 23
Transcripts
RGLS
Earnings call transcript
2022 Q3
11 Nov 22
RGLS
Earnings call transcript
2022 Q2
11 Aug 22
RGLS
Earnings call transcript
2022 Q1
13 May 22
RGLS
Earnings call transcript
2021 Q4
11 Mar 22
RGLS
Earnings call transcript
2021 Q3
11 Nov 21
RGLS
Earnings call transcript
2021 Q2
11 Aug 21
RGLS
Earnings call transcript
2021 Q1
14 May 21
RGLS
Earnings call transcript
2018 Q1
10 May 18
RGLS
Earnings call transcript
2017 Q4
7 Mar 18
RGLS
Earnings call transcript
2017 Q3
7 Nov 17
Latest ownership filings
SC 13G
RA CAPITAL MANAGEMENT, L.P.
25 Mar 24
SC 13G
Deep Track Capital, LP
22 Mar 24
SC 13G
Vivo Opportunity Fund Holdings, L.P.
20 Mar 24
SC 13D/A
Growth Equity Opportunities V, LLC
18 Mar 24
4
STELIOS PAPADOPOULOS
15 Mar 24
SC 13G
DAFNA Capital Management LLC
14 Feb 24
SC 13G/A
FMR LLC
9 Feb 24
SC 13G/A
VICTORY CAPITAL MANAGEMENT INC
6 Feb 24
4
CRISPINA CALSADA
18 Jan 24
4
Christopher Ray Aker
18 Jan 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 25.90 mm | 25.90 mm | 25.90 mm | 25.90 mm | 25.90 mm | 25.90 mm |
Cash burn (monthly) | 3.81 mm | (no burn) | 2.71 mm | 2.48 mm | 2.09 mm | 2.24 mm |
Cash used (since last report) | 22.77 mm | n/a | 16.19 mm | 14.81 mm | 12.51 mm | 13.40 mm |
Cash remaining | 3.12 mm | n/a | 9.71 mm | 11.08 mm | 13.39 mm | 12.50 mm |
Runway (months of cash) | 0.8 | n/a | 3.6 | 4.5 | 6.4 | 5.6 |
Institutional ownership, Q2 2023
30.3% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 27 |
Opened positions | 1 |
Closed positions | 2 |
Increased positions | 11 |
Reduced positions | 2 |
13F shares | Current |
---|---|
Total value | 12.01 bn |
Total shares | 19.84 mm |
Total puts | 100.00 |
Total calls | 65.22 k |
Total put/call ratio | 0.0 |
Largest owners | Shares | Value |
---|---|---|
Biotechnology Value Fund L P | 9.66 mm | $0.00 |
FHI Federated Hermes Inc - Ordinary Shares | 3.88 mm | $5.70 bn |
FMR | 2.21 mm | $3.24 bn |
Growth Equity Opportunities V | 1.95 mm | $2.37 mm |
DAFNA Capital Management | 1.11 mm | $1.63 bn |
Vanguard | 282.66 k | $415.51 mm |
Victory Capital Management | 221.51 k | $325.61 mm |
Sarissa Capital Management | 185.18 k | $272.22 mm |
Geode Capital Management | 112.62 k | $165.55 mm |
Renaissance Technologies | 46.10 k | $68.00 k |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
14 Mar 24 | Papadopoulos Stelios | Common Stock | Grant | Acquire A | No | No | 1.6 | 250,000 | 400.00 k | 978,388 |
18 Jan 24 | Hagan Joseph P | Common Stock | Sell | Dispose S | No | Yes | 1.1906 | 14,580 | 17.36 k | 57,112 |
18 Jan 24 | Aker Christopher Ray | Common Stock | Sell | Dispose S | No | Yes | 1.1906 | 5,468 | 6.51 k | 10,056 |
18 Jan 24 | Crispina Calsada | Common Stock | Sell | Dispose S | No | No | 1.1906 | 5,468 | 6.51 k | 5,782 |
12 Jan 24 | Preston Klassen | Stock Option Common Stock | Grant | Acquire A | No | No | 1.3 | 120,000 | 156.00 k | 120,000 |
News
HC Wainwright & Co. Reiterates Buy on Regulus Therapeutics, Maintains $9 Price Target
25 Mar 24
Regulus Therapeutics Q4 EPS $(0.40) Misses $(0.39) Estimate
21 Mar 24
Canaccord Genuity Maintains Buy on Regulus Therapeutics, Lowers Price Target to $11
19 Mar 24
Leerink Partners Initiates Coverage On Regulus Therapeutics with Outperform Rating, Announces Price Target of $6
18 Mar 24
Why Limbach Holdings Shares Are Trading Lower By Around 15%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
14 Mar 24
Press releases
Regulus Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Updates
21 Mar 24
Emerging Companies: Key Developments and Investment Insights RGLS, INBS, VTAK, DYAI, TCBP
13 Mar 24
Thinking about buying stock in BigBear.ai, Nukkleus, Singularity Future Technology, Regulus Therapeutics, or ATRenew?
12 Mar 24
Regulus Therapeutics Announces Oversubscribed $100 Million Private Placement of Equity
12 Mar 24
Regulus Therapeutics Announces Positive Topline Data from the Second Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
12 Mar 24